Kite Pharma is a California-based biopharmaceutical company working on various types of cell therapies for the treatment of cancer, in a bid to become the first pharmaceutical firm to gain successful FDA approval for this new class of cancer treatment.
Kite closely collaborates with the National Cancer Institute, which conducted significant early research into the forms of cell therapies that Kite is seeking to commercialize. NCI conducts clinical trials under Cooperative Research and Development Agreements (CRADAs) with Kite, and additionally has granted exclusive licenses on over a dozen patents to Kite on the same technologies.
Below are selected news stories and press releases related to the development history of Kite’s pipeline, as well as its relationship with the National Institutes of Health.
For more information on Kite’s relationship with the NIH, see here: /node/2640.
19 October 2016. Ned Pagliarulo. “CAR-T ready for flight, says Kite.” BioPharma Dive.
21 September 2016. Cheryl Swanson. “Juno Therapeutics and Kite Pharma: The Danger of Alarmingly Thin Data.” The Motley Fool.
20 September 2016. “Kite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates to Treat Solid Tumors Expressing Mutated KRAS.” Kite Pharma Press Release.
1 August 2016. Andrew Pollack. “Setting the Body’s ‘Serial Killers’ Loose on Cancer.” New York Times.
27 July 2016. “Kite Pharma Announces Exclusive License with the National Institutes of Health for Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate to Treat B-Cell Malignancies.” Kite Pharma Press Release.
7 July 2016. Edwin Lopez. “Five NCI cell therapy studies resume production after April halt.” BioPharma Dive.
20 June 2016. “Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI).” Kite Pharma Press Release.
6 June 2016. “Kite/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions in Advanced Non-Hodgkin Lymphoma.” Kite Pharma Press Release.
4 June 2016. Deena Beasley. “Cancer cell therapies could be approved next year: Juno, Kite Pharma.” Reuters.
2 June 2016. Nicole Gray. “Kite Pharma rides CAR-T momentum into ASCO.” BioPharma Dive.
19 April 2016. Nell Greenfieldboyce. “NIH Halts Some Research Amid Concerns Over Contamination And Safety.” NPR.
17 April 2016. Caroline Chen. “Kite Cancer Therapy Responses in Solid Tumors Sustained in Trial.” Bloomberg.
3 April 2016. Brian Feroldi. “This Could Be the Next Big Pharma Buyout.” The Motley Fool.
26 February 2016. Arlene Weintraub. “Kite Pharma’s CEO On Cancer-Killing T-Cells: ‘This Is A Revolution.’” Forbes.
7 January 2016. “Kite Pharma Expands Its Clinical and Research Partnership With the National Cancer Institute (NCI) for Next-Generation CAR Programs to Treat B-Cell Malignancies.” Kite Pharma Press Release.
17 October 2015. Stuart Pfeifer. “High-flying Kite could score big with new cancer treatment. Los Angeles Times.
1 October 2015. “Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers.” Kite Pharma Press Release.
1 May 2015. Caleb Melby and Brandon Kochkodin. “Kite Pharma CEO May Halve Tax Bill on $95 Million in Options.” Bloomberg.
18 March 2015. “Kite Pharma Acquires T-Cell Factory for $21M Up Front.” GEN News Highlights.
2 March 2015. John Carroll. “Kite Pharma doubles down on crucial NCI partnership, expands work on CAR-T/TCRs.” FierceBiotech.
2 March 2015. “Kite Pharma Expands Its Research and Development Collaboration With the National Cancer Institute to Develop a Next Generation of Cancer Immunotherapy Products for Solid Tumors.” Kite Pharma Press Release.
7 January 2015. “Kite Pharma Announces Exclusive License With the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat HPV-Associated Cancers.” Kite Pharma Press Release.
25 August 2014. John Carroll. “UPDATED: Kite Pharma spikes on its second take of CAR-T cancer study.” FierceBiotech.
6 June 2014. “Kite Pharma Announces Exclusive License with The National Institutes of Health for T Cell Receptor (TCR)-Based Products Targeting NY-ESO-1 For Multiple Cancer Indications.” Kite Pharma Press Release.
8 May 2014. Maggie Fox. “New Immune Therapy Approach Tackles Woman’s Rare Cancer. NBC News.
7 May 2014. Matthew Herper. “Is This How We’ll Cure Cancer?” Forbes.
7 December 2013. “Kite Pharma’s Lead Program with the National Cancer Institute (NCI) Demonstrates Positive Results in Patients with Aggressive Non-Hodgkin’s Lymphoma.” Kite Pharma Press Release.
15 May 2013. “UPDATED: Billionaires back Kite Pharma in $20M raise for cancer immunotherapies.” FierceBiotech.
16 October 2012. “Kite Pharma Partners with the National Cancer Institute to Develop Novel Cellular Immunotherapy Clinical Products.” Kite Pharma Press Release.